{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:37:03Z","timestamp":1790285823769,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Bronchiolitis obliterans syndrome (BOS), as chronic manifestation of graft-versus-host disease (GVHD), is a debilitating complication leading to lung function deterioration in patients after allogeneic hematopoietic cell transplantation (allo-HCT). In the present study, we evaluated BOS development risk in patients after receiving myeloablative conditioning (MAC) regimens. We performed a retrospective analysis of patients undergoing allo-HCT, who received MAC with busulfan\/cyclophosphamid (BuCy,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009175) busulfan\/fludarabin (FluBu4,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200929) or thiotepa\/busulfan\/fludarabine (TBF MAC,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200937). The prevalence of lung disease prior allo-HCT, smoking status, GvHD prophylaxis, HCT-CI score, EBMT risk score and GvHD incidence varied across the groups. The cumulative incidence of BOS using the NIH diagnosis consensus criteria at 2 years after allo-HCT was 8% in FluBu4, 23% in BuCy and 19% in TBF MAC (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.07). In the multivariate analysis, we identified associated factors for time to BOS such as FEV1&lt;median (99% of predicted) (HR\u2009=\u20092.39,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.004), CMV patient serology positivity (HR\u2009=\u20092.11,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.014), TLC\u2009&lt;\u200980% of predicted (HR\u2009=\u20090.12,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.02) and GvHD prophylaxis with in vivo T-cell depletion (HR\u2009=\u20090.29,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001) as predictors of BOS. In summary, we identified risk factors for BOS development in patients receiving MAC conditioning. These findings might serve to identify patients at risk, who might benefit from closely monitoring or early therapeutic interventions.\n                  <\/jats:p>","DOI":"10.1038\/s41409-024-02422-z","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T09:03:44Z","timestamp":1727427824000},"page":"1744-1753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evaluation of risk for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens"],"prefix":"10.1038","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8287-5673","authenticated-orcid":false,"given":"Jes\u00fas","family":"Duque-Afonso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraschiva","family":"Rassner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Walther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8091-1589","authenticated-orcid":false,"given":"Gabriele","family":"Ihorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5037-6175","authenticated-orcid":false,"given":"Claudia","family":"Wehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0813-3444","authenticated-orcid":false,"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3805-8123","authenticated-orcid":false,"given":"Hartmut","family":"Bertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn Christian","family":"Frye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiana","family":"Stolz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6565-3393","authenticated-orcid":false,"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1799-5927","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1788-2807","authenticated-orcid":false,"given":"Kristina","family":"Maas-Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"2422_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2016-06-686618","volume":"129","author":"KP MacDonald","year":"2017","unstructured":"MacDonald KP, Hill GR, Blazar BR. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood. 2017;129:13\u201321.","journal-title":"Blood."},{"key":"2422_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2033122","volume":"385","author":"R Zeiser","year":"2021","unstructured":"Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med. 2021;385:228\u201338.","journal-title":"N Engl J Med."},{"key":"2422_CR3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ccm.2016.12.013","volume":"38","author":"A Bergeron","year":"2017","unstructured":"Bergeron A. Late-onset noninfectious pulmonary complications after allogeneic hematopoietic stem cell transplantation. Clin Chest Med. 2017;38:249\u201362.","journal-title":"Clin Chest Med"},{"key":"2422_CR4","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1182\/blood-2016-08-693507","volume":"129","author":"KM Williams","year":"2017","unstructured":"Williams KM. How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Blood. 2017;129:448\u201355.","journal-title":"Blood."},{"key":"2422_CR5","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/bmt.2011.35","volume":"46","author":"GC Hildebrandt","year":"2011","unstructured":"Hildebrandt GC, Fazekas T, Lawitschka A, Bertz H, Greinix H, Halter J, et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transpl. 2011;46:1283\u201395.","journal-title":"Bone Marrow Transpl"},{"key":"2422_CR6","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1182\/blood-2002-10-3289","volume":"102","author":"E Sakaida","year":"2003","unstructured":"Sakaida E, Nakaseko C, Harima A, Yokota A, Cho R, Saito Y, et al. Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect. Blood. 2003;102:4236\u201342.","journal-title":"Blood."},{"key":"2422_CR7","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945\u201356.","journal-title":"Biol Blood Marrow Transpl."},{"key":"2422_CR8","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1182\/bloodadvances.2021006885","volume":"6","author":"Y Pang","year":"2022","unstructured":"Pang Y, Charya AV, Keller MB, Sirajuddin A, Fu YP, Holtzman NG, et al. The ISHLT chronic lung allograft dysfunction consensus criteria are applicable to pulmonary chronic graft-versus-host disease. Blood Adv. 2022;6:4196\u2013207.","journal-title":"Blood Adv"},{"key":"2422_CR9","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/sj.bmt.1704426","volume":"33","author":"F Patriarca","year":"2004","unstructured":"Patriarca F, Skert C, Sperotto A, Damiani D, Cerno M, Geromin A, et al. Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation. Bone Marrow Transpl. 2004;33:751\u20138.","journal-title":"Bone Marrow Transpl."},{"key":"2422_CR10","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.bbmt.2015.10.009","volume":"22","author":"KM Williams","year":"2016","unstructured":"Williams KM, Cheng GS, Pusic I, Jagasia M, Burns L, Ho VT, et al. Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2016;22:710\u20136.","journal-title":"Biol Blood Marrow Transpl."},{"key":"2422_CR11","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1164\/rccm.201410-1818OC","volume":"191","author":"A Bergeron","year":"2015","unstructured":"Bergeron A, Chevret S, Chagnon K, Godet C, Bergot E, Peffault de Latour R, et al. Budesonide\/Formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2015;191:1242\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"2422_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12931-016-0380-1","volume":"17","author":"SW Kim","year":"2016","unstructured":"Kim SW, Rhee CK, Kim YJ, Lee S, Kim HJ, Lee JW. Therapeutic effect of budesonide\/formoterol, montelukast and N-acetylcysteine for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Respir Res 2016;17:63.","journal-title":"Respir Res"},{"key":"2422_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jama.2017.9938","volume":"318","author":"A Bergeron","year":"2017","unstructured":"Bergeron A, Chevret S, Granata A, Chevallier P, Vincent L, Huynh A, et al. Effect of azithromycin on airflow decline-free survival after allogeneic hematopoietic stem cell transplant: the ALLOZITHRO randomized clinical trial. JAMA. 2017;318:557\u201366.","journal-title":"JAMA."},{"key":"2422_CR14","doi-asserted-by":"crossref","unstructured":"Bos S, Murray J, Marchetti M, Cheng GS, Bergeron A, Wolff D, et al. ERS\/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults. Eur Respir J. 2024;63:2301727.","DOI":"10.1183\/13993003.01727-2023"},{"key":"2422_CR15","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood."},{"key":"2422_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.7326\/0003-4819-144-6-200603210-00007","volume":"144","author":"T Parimon","year":"2006","unstructured":"Parimon T, Au DH, Martin PJ, Chien JW. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med. 2006;144:407\u201314.","journal-title":"Ann Intern Med."},{"key":"2422_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.bbmt.2009.09.016","volume":"16","author":"A Ramirez-Sarmiento","year":"2010","unstructured":"Ramirez-Sarmiento A, Orozco-Levi M, Walter EC, Au MA, Chien JW. Influence of pretransplantation restrictive lung disease on allogeneic hematopoietic cell transplantation outcomes. Biol Blood Marrow Transpl. 2010;16:199\u2013206.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2422_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bbmt.2009.08.016","volume":"16","author":"EC Walter","year":"2010","unstructured":"Walter EC, Orozco-Levi M, Ramirez-Sarmiento A, Vigorito A, Campregher PV, Martin PJ, et al. Lung function and long-term complications after allogeneic hematopoietic cell transplant. Biol Blood Marrow Transpl. 2010;16:53\u201361.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2422_CR19","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1182\/blood.V70.5.1382.1382","volume":"70","author":"PJ Tutschka","year":"1987","unstructured":"Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood. 1987;70:1382\u20138.","journal-title":"Blood."},{"key":"2422_CR20","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","volume":"16","author":"A Rambaldi","year":"2015","unstructured":"Rambaldi A, Grassi A, Masciulli A, Boschini C, Mic\u00f2 MC, Busca A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015;16:1525\u201336.","journal-title":"Lancet Oncol"},{"key":"2422_CR21","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/bmt.2012.13","volume":"47","author":"J Sanz","year":"2012","unstructured":"Sanz J, Boluda JC, Mart\u00edn C, Gonz\u00e1lez M, Ferr\u00e1 C, Serrano D, et al. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transpl. 2012;47:1287\u201393.","journal-title":"Bone Marrow Transpl"},{"key":"2422_CR22","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1182\/blood-2012-08-453399","volume":"121","author":"P Di Bartolomeo","year":"2013","unstructured":"Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo L, Cerretti R, et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood. 2013;121:849\u201357.","journal-title":"Blood."},{"key":"2422_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","volume":"19","author":"AM Raiola","year":"2013","unstructured":"Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transpl. 2013;19:117\u201322.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2422_CR24","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.bbmt.2019.05.014","volume":"25","author":"T Pagliardini","year":"2019","unstructured":"Pagliardini T, Castagna L, Harbi S, Porta MD, Rey J, F\u00fcrst S, et al. Thiotepa, fludarabine, and busulfan conditioning regimen before T cell-replete haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia: a bicentric experience of 100 patients. Biol Blood Marrow Transpl. 2019;25:1803\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2422_CR25","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1016\/j.bbmt.2018.06.024","volume":"24","author":"J Duque-Afonso","year":"2018","unstructured":"Duque-Afonso J, Ihorst G, Waterhouse M, Zeiser R, W\u00e4sch R, Bertz H, et al. Impact of lung function on bronchiolitis obliterans syndrome and outcome after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning. Biol Blood Marrow Transpl. 2018;24:2277\u201384.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2422_CR26","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/bmt.2013.3","volume":"48","author":"J Duque-Afonso","year":"2013","unstructured":"Duque-Afonso J, Ihorst G, W\u00e4sch R, Bertz H, M\u00fcller-Quernheim J, Finke J, et al. Identification of risk factors for bronchiolitis obliterans syndrome after reduced toxicity conditioning before hematopoietic cell transplantation. Bone Marrow Transpl. 2013;48:1098\u2013103.","journal-title":"Bone Marrow Transpl"},{"key":"2422_CR27","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","volume":"10","author":"J Finke","year":"2009","unstructured":"Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855\u201364.","journal-title":"Lancet Oncol"},{"key":"2422_CR28","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1016\/S2352-3026(17)30081-9","volume":"4","author":"J Finke","year":"2017","unstructured":"Finke J, Schmoor C, Bethge WA, Ottinger H, Stelljes M, Volin L, et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematol. 2017;4:e293\u2013e301.","journal-title":"Lancet Haematol."},{"key":"2422_CR29","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.bbmt.2009.08.002","volume":"15","author":"H Bertz","year":"2009","unstructured":"Bertz H, Spyridonidis A, W\u00e4sch R, Gr\u00fcllich C, Egger M, Finke J. A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation. Biol Blood Marrow Transpl. 2009;15:1563\u201370.","journal-title":"Biol Blood Marrow Transpl."},{"key":"2422_CR30","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/BF02718260","volume":"168","author":"AW Zaiss","year":"1990","unstructured":"Zaiss AW, Matthys H. A multiuser system for whole body plethysmographic measurements and interpretation. Lung. 1990;168:1185\u201392.","journal-title":"Lung."},{"key":"2422_CR31","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transpl. 2015;21:389\u2013401.e1.","journal-title":"Biol Blood Marrow Transpl."},{"key":"2422_CR32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2991\/chi.d.191207.001","volume":"2","author":"AS Kanate","year":"2020","unstructured":"Kanate AS, Nagler A, Savani B. Summary of scientific and statistical methods, study endpoints and definitions for observational and registry-based studies in hematopoietic cell transplantation. Clin Hematol Int. 2020;2:2\u20134.","journal-title":"Clin Hematol Int"},{"key":"2422_CR33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/sim.4780050306","volume":"5","author":"EL Korn","year":"1986","unstructured":"Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med. 1986;5:255\u201360.","journal-title":"Stat Med."},{"key":"2422_CR34","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1200\/JCO.2007.12.9866","volume":"26","author":"JJ Dignam","year":"2008","unstructured":"Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol. 2008;26:4027\u201334.","journal-title":"J Clin Oncol."},{"key":"2422_CR35","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc."},{"key":"2422_CR36","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.bbmt.2005.12.034","volume":"12","author":"A Bacigalupo","year":"2006","unstructured":"Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transpl. 2006;12:560\u20135.","journal-title":"Biol Blood Marrow Transpl."},{"key":"2422_CR37","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.1182\/blood-2011-01-329821","volume":"117","author":"G Soci\u00e9","year":"2011","unstructured":"Soci\u00e9 G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood. 2011;117:6375\u201382.","journal-title":"Blood."},{"key":"2422_CR38","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/ajh.23656","volume":"89","author":"L Gazourian","year":"2014","unstructured":"Gazourian L, Rogers AJ, Ibanga R, Weinhouse GL, Pinto-Plata V, Ritz J, et al. Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Am J Hematol. 2014;89:404\u20139.","journal-title":"Am J Hematol."},{"key":"2422_CR39","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1164\/rccm.200911-1786OC","volume":"181","author":"LD Snyder","year":"2010","unstructured":"Snyder LD, Finlen-Copeland CA, Turbyfill WJ, Howell D, Willner DA, Palmer SM. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med. 2010;181:1391\u20136.","journal-title":"Am J Respir Crit Care Med."},{"key":"2422_CR40","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/j.1600-0609.1986.tb02287.x","volume":"36","author":"N Jacobsen","year":"1986","unstructured":"Jacobsen N, Andersen HK, Skinh\u00f8j P, Ryder LP, Platz P, Jerne D, et al. Correlation between donor cytomegalovirus immunity and chronic graft-versus-host disease after allogeneic bone marrow transplantation. Scand J Haematol. 1986;36:499\u2013506.","journal-title":"Scand J Haematol"},{"key":"2422_CR41","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1182\/bloodadvances.2022009112","volume":"7","author":"M Ueda Oshima","year":"2023","unstructured":"Ueda Oshima M, Xie H, Zamora D, Flowers ME, Hill GR, Mielcarek MB, et al. Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation. Blood Adv. 2023;7:1394\u2013403.","journal-title":"Blood Adv"},{"key":"2422_CR42","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.bbmt.2010.03.020","volume":"16","author":"N Cantoni","year":"2010","unstructured":"Cantoni N, Hirsch HH, Khanna N, Gerull S, Buser A, Bucher C, et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transpl. 2010;16:1309\u201314.","journal-title":"Biol Blood Marrow Transpl."},{"key":"2422_CR43","doi-asserted-by":"publisher","first-page":"4984","DOI":"10.1182\/bloodadvances.2022008201","volume":"6","author":"A Sheshadri","year":"2022","unstructured":"Sheshadri A, Huang HJ, Bashoura L, Alousi AM, Alkhunaizi M, Sharifi H, et al. Graft-versus-host disease may cause pulmonary restriction, but not all restriction is graft-versus-host disease. Blood Adv. 2022;6:4984\u20136.","journal-title":"Blood Adv"},{"key":"2422_CR44","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.1016\/j.bbmt.2009.11.002","volume":"16","author":"JW Chien","year":"2010","unstructured":"Chien JW, Duncan S, Williams KM, Pavletic SZ. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2010;16:S106\u201314.","journal-title":"Biol Blood Marrow Transpl."},{"key":"2422_CR45","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1016\/S2214-109X(22)00456-9","volume":"11","author":"B Knox-Brown","year":"2023","unstructured":"Knox-Brown B, Patel J, Potts J, Ahmed R, Aquart-Stewart A, Cherkaski HH, et al. Small airways obstruction and its risk factors in the Burden of Obstructive Lung Disease (BOLD) study: a multinational cross-sectional study. Lancet Glob Health. 2023;11:e69\u2013e82.","journal-title":"Lancet Glob Health."},{"key":"2422_CR46","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S2213-2600(20)30155-7","volume":"8","author":"D Xiao","year":"2020","unstructured":"Xiao D, Chen Z, Wu S, Huang K, Xu J, Yang L, et al. Prevalence and risk factors of small airway dysfunction, and association with smoking, in China: findings from a national cross-sectional study. Lancet Respir Med. 2020;8:1081\u201393.","journal-title":"Lancet Respir Med."}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02422-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02422-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02422-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T13:03:03Z","timestamp":1733144583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02422-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2422"],"URL":"https:\/\/doi.org\/10.1038\/s41409-024-02422-z","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"22 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicting financial interest with the submission of this article. JF received research support and speakers honoraria from Medac, Neovii and Riemser. JD-A received speaker\u2019s honoraria from Roche, Amgen, AstraZeneca, Riemser, Sobi, Lilly, Beigene and Ipsen and travel support from Gilead, Sobi, Beigene, Alexion and Abbvie. RZ received speaker\u2019s honoraria from Incyte, Novartis, Roche and Mallinckroth. D Stolz reports personal fees from CSL Behring, Berlin-Chemie Menarini, Novartis, GlaxoSmithKline, AstraZeneca, Vifor, Merck, Chiesi, Grifols, MSD, Merck, Sanofi, Roche, Boehringer-Ingelheim and Pfizer, and participation on advisory boards for CSL Behring, Berlin-Chemie, Menarini, Novartis, Boehringer-Ingelheim, GlaxoSmithKline, AstraZeneca, Vifor, Merck, Chiesi, Roche, Grifols, MSD, Merck and Sanofi. This project was supported by a grant of the German Federal Ministry of Education and Research (BMBF 01 EO 0803). JD-A received support from Else Kr\u00f6ner-Fresenius-Stiftung (Nr. 2018-A56). JD-A received research support from German Research Foundation (Deutsche Forschungsgemeinschaft, ref. DU 1287\/3-1 and 1287\/5-1), from the Forschungskommission of the University of Freiburg Medical School (DUQ1106\/16) and Berta Ottenstein-Programm for Advanced Clinician Scientists, Faculty of Medicine, University of Freiburg. KM-B received support from Else-Kr\u00f6ner-Fresenius-Stiftung (2021_EKEA.131), the\u00a0Berta-Ottenstein Program (Faculty of Medicine, Freiburg University),\u00a0and the IMMediate Advanced Clinician Scientist-Program, Department of Medicine II, Medical Center \u2013 University of Freiburg and Faculty of Medicine, University of Freiburg, funded by the Bundesministerium f\u00fcr Bildung und Forschung (BMBF, Federal Ministry of Education and Research) - 01EO2103.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}